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ABSTRACT
Systemic analysis of available large-scale
biological/biomedical data is critical for study-
ing biological mechanisms, and developing novel
and effective treatment approaches against dis-
eases. However, different layers of the available
data are produced using different technologies and
scattered across individual computational resources
without any explicit connections to each other, which
hinders extensive and integrative multi-omics-based
analysis. We aimed to address this issue by de-
veloping a new data integration/representation
methodology and its application by construct-
ing a biological data resource. CROssBAR is a
comprehensive system that integrates large-scale
biological/biomedical data from various resources
and stores them in a NoSQL database. CROssBAR
is enriched with the deep-learning-based prediction
of relationships between numerous data entries,
which is followed by the rigorous analysis of the
enriched data to obtain biologically meaningful
modules. These complex sets of entities and
relationships are displayed to users via easy-to-
interpret, interactive knowledge graphs within an
open-access service. CROssBAR knowledge graphs
incorporate relevant genes-proteins, molecular
interactions, pathways, phenotypes, diseases, as
well as known/predicted drugs and bioactive com-
pounds, and they are constructed on-the-fly based
on simple non-programmatic user queries. These
intensely processed heterogeneous networks are
expected to aid systems-level research, especially
to infer biological mechanisms in relation to genes,
proteins, their ligands, and diseases.
INTRODUCTION
Data driven approaches are rising as strong candidates to
aid researchers in proposing effective personalized solu-
tions especially to complex diseases, with their capabili-
ties regarding the comprehensive analysis of available large-
scale biological and biomedical data. One critical short-
coming here is related to data connectivity. Different in-
stitutions, with their distinct expertise and infrastructure,
continuously update and maintain specific parts of the
complex biomedical data. For this reason, connections be-
tween data-points across different resources are neither
well-established nor explicit, even though entities are bio-
logically related and complementary to each other. In ad-
dition to the connectivity problem, another issue related to
biomedical data is the incompleteness in knowledge space
(e.g. little is known about the possible ligands of a tar-
get biomolecule, or the phenotypic implications of a newly
identified variant). There is a clear requirement for in-
novative computational approaches to integrate available
biomedical big-data and to complete missing information
with accurate in silico associations.
There are studies, tools and resources that integrate
biological data (either from other data sources or by
direct curation) and communicate it via textual or vi-
sual representations. One of the most commonly used
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resources in this sense are biological pathway databases
such as Reactome (1), KEGG (2) and WikiPathways (3),
where the interactions/reactions are communicated via net-
work representations. STRING and STITCH databases are
two well-known molecular interaction services, in which
protein-protein and protein-chemical interactions are inte-
grated from various resources, including both experimen-
tally proven and electronically predicted data points, and
presented to users as pre-computed networks (4,5). Gene-
MANIA is an online platform for exploring the relation-
ships between genes over network representations generated
by utilizing large-scale genomics and proteomics data, for
gene prioritization and function prediction (6). Apart from
these well-known resources, there are other relevant stud-
ies in the literature. One of the earliest applications of the
integration of structured biomedical data was about relat-
ing semantically same or similar terms from different onto-
logical systems (without providing any visual output) (7,8).
Another one of the early applications of heterogeneous
biomedical data integration was the BioGraph data min-
ing platform, which is shown to be successfully utilized for
disease gene prioritization via random walks on the gener-
ated network (9). In the Bio4j project, authors aimed to con-
struct a graph-based platform as an infrastructure for inte-
grating biological data. They stored public data obtained
from sources such as UniProt, Gene Ontology and Expasy
in independent graphs to be queried via domain specific
languages such as Angulillos (10). In project Rephetio, au-
thors systematically integrated biomedical data from vari-
ous resources and stored them in a graph database to con-
struct the Hetionet resource, with the primary purpose of
inferring new drug/compound–disease relations. Hetionet
can be browsed by users via database queries in Cypher
language (11). With a similar approach, BioGrakn project
aimed to construct a biomedical knowledge graph (KG) us-
ing the Grakn database infrastructure. Users are required to
download and run the system locally, which can be queried
via the Graql language (12). Another system named Bio-
Graph integrates gene/protein, function and cancer related
miRNA data from various source databases and lets users
to query the data using Gremlin query language to produce
information on returned entities and simple network-based
visualizations (13). In a few studies, authors discussed al-
ternative ways of extracting and relating biomedical data;
(i) from the literature (i.e. articles and similar unstructured
textual sources) via text mining (14–17), and (ii) from public
biological databases providing ontological data via seman-
tic integration (18), with the aim of constructing biomedi-
cal knowledge bases or graphs. Two recent studies evaluated
and discussed the use of Wikidata, which is a community-
driven semantic knowledge base, as data resource and in-
frastructure for the generation of biomedical knowledge
graphs, over use cases and potential applications (19,20).
Lately, numerous bio-pharmaceutical companies start in-
vesting in biomedical data integration and mining using
graph databases and knowledge graph-based representa-
tions (21,22).
Apart from the few widely adopted tools and services,
many of the studies mentioned above, especially the ones
dealing with heterogeneous biological data, suffer from is-
sues that limit their functionality and/or usability. For ex-
ample, some of them require highly specialized inputs from
users, such as complex database queries, to generate the de-
sired output, which may not be easy for researchers with
little or no programmatic background. Some others do not
provide an easily-interpretable visualization of the output
data, which decreases their usability, since a complex corpus
of information is usually hard to consume (without further
computational analysis) when communicated only via tex-
tual or tabular definitions. Additionally, some resources are
not properly maintained, causing the size and the content of
the incorporated data to fall behind. In some cases, the au-
thors just published a large dataset (e.g. a graph) for users to
download, without any means of a relevant interactive sub-
set generation, based on user queries. Finally, considering
the proprietary resources belonging to pharmaceutical/bio-
development companies, which are claimed to fulfil most
of the current biomedical data integration and representa-
tion requirements, these tools and services are only utilized
internally (in the course of their drug discovery and devel-
opment projects), not open to public research. Our litera-
ture review revealed that there is a critical requirement for
fully open access, continuously updated and online biomed-
ical data integration and representation tools/services with
coding-free user interfaces, combined with cutting-edge ar-
tificial intelligence-based data enrichment applications, to
be freely and easily used by the life-sciences research com-
munity.
In this study, we aimed to address these shortcomings by
developing a computational method for integrating, repre-
senting and visualizing heterogeneous biological data, to-
gether with the application of this method as a comprehen-
sive open access system entitled CROssBAR. For this, we
first integrated various well-known biological data sources
and established a new database. Second, we enriched the
data by inferring the missing relations between existing data
points via building and applying machine learning mod-
els. Third, we constructed informative knowledge graphs
based on specific user queries of single or multiple biomedi-
cal components/terms such as a gene, protein, disease, phe-
notype, pathway, drug and/or compound. Schematic rep-
resentation of the study is given in Figure 1A. CROssBAR
is available as a web-service/tool at https://crossbar.kansil.
org.
In the following sections, we explain the methodological
design of CROssBAR and present the results of its applica-
tion with a use case, the coronavirus disease 2019 (COVID-
19) knowledge graph, and two data exploration examples.
We also conducted an in vitro study in terms of measur-
ing the changes in gene expression of Chloroquine Phos-
phate (CQ) treated liver cells and comparing the results with
COVID-19 KGs. Finally, we discussed the diversity and sta-
bility of the content of CROssBAR knowledge graphs over
data-centric analyses.
MATERIAL AND METHODS
CROssBAR database and API
Integrated data resources and the CROssBAR-DB. We de-
veloped extract-transform-load (ETL) pipelines in Java 8
using the Spring batch framework to structure the jobs in
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Figure 1. (A) Overall schematic representation of the CROssBAR system within five main pillars; (i) large-scale biological and biomedical data integration,
(ii) deep-learning based prediction of missing relations, (iii) construction of knowledge graph representations with serial association and filtering operations,
(iv) experimental validation of the computational results and (v) open-access web-service with an easy-to-use interface and rich visualization options and
(B) different types of biological/biomedical components and relationships, and their visual representation in CROssBAR knowledge graphs as nodes and
edges.
art EMBL-EBI LSF clusters in a parallel distributed fash-
ion to reduce the processing time. The data are finally stored
in MongoDB in the form of independent data collections,
thus, providing schemaless flexibility and faster develop-
ment, while sustaining data relationships in the form of
nested documents. The pipelines have been both unit and
integration tested using Spock framework in Groovy lan-
guage.
The public databases integrated in the CROss-
BAR system can be listed along with the type of the
biological/biomedical data they contain as follows:
(i) UniProt Knowledgebase (protein sequence and anno-
tations including functions, domains, families, inter-
actions, disease relations, pathway memberships, and
more),
(ii) IntAct (protein-protein interactions),
(iii) InterPro (protein domain and family information),
(iv) DrugBank (approved and investigational drugs and
their targets),
(v) ChEMBL (small molecule compounds, targets,
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(vi) PubChem (small molecule compounds, targets, bioas-
says and bioactivities collected from various re-
sources),
(vii) Reactome (pathway entries and their relations to pro-
teins, currently incorporated directly from UniProt),
(viii) KEGG (pathway and disease entries together with
their relations to genes, currently not direct part of
CROssBAR-DB),
(ix) Experimental Factor Ontology – EFO (disease terms
integrated from multiple disease-centric databases in-
cluding OMIM and Orphanet, organized under an
ontological system) and
(x) Human Phenotype Ontology – HPO (phenotypic ab-
normality terms that relate to both genes and disease
entries).
These biological/biomedical entity types and their rela-
tions are displayed in Figure 1B as nodes and edges of a net-
work. CROssBAR-DB schema-like representation is pro-
vided both in Figure 2A and in the GitHub repository of
the project (https://github.com/cansyl/CROssBAR), where
the attributes/fields belonging to each collection can be ob-
served in full detail. The statistics regarding the number of
terms and annotations incorporated into CROssBAR-DB
from each resource listed above is given in Figure 2B.
Obtaining biomedical data via the CROssBAR-API.
CROssBAR data services (CROssBAR-API) are de-
veloped in Java 8 using Spring Boot’s web module in
a RESTful architecture style. The API currently pro-
vides 13 endpoints documented using Swagger API
which allows endpoints to be tested within the docu-
mentation, and gives all information about the expected
response schema. The API leverages the CROssBAR-
DB hosted in a MongoDB platform to fetch data and
filter results for users. The web services have been both
unit and integration tested using Spock framework in
Groovy language. CROssBAR-API is publicly available
at https://www.ebi.ac.uk/Tools/crossbar/swagger-ui.html,
where users can query independent collections over the
indexed attributes/fields. Screenshots of the Swagger
API are given in the Supplementary Figure S2, where 13
CROssBAR-DB collections are shown. Here, the collec-
tions entitled ‘Activities’, ‘Assays’, ‘Molecules’ and ‘Targets’
correspond to bioactivity, bioassay, compound and target
entries in the ChEMBL database, respectively. ‘Drugs’ cor-
responds to drug entries in DrugBank, ‘EFO disease terms’
corresponds to the disease entries in the Experimental
Factor Ontology, ‘HPO’ corresponds to phenotype entries
in the Human Phenotype Ontology, ‘Proteins’ correspond
to a subset of the protein entries in the UniProtKB, and
‘Intact’ refers to protein-protein interactions that belong
to entries in the Proteins collection. The remaining four
collections belong to the PubChem data. There is no
one-to-one correspondence between the incorporated data
resources and the CROssBAR-DB collections since some
of the resources had to be split to multiple collections for
easier query (e.g. ChEMBL and PubChem). Also, some
of the sources are directly incorporated from the UniProt
database, thus, reside in the proteins collection (e.g. both
terms and annotations for InterPro, Reactome, and only
annotations for OMIM and Orphanet).
It is possible to obtain cross-collection relational data
(i.e. integrated relational data from multiple collections) by
writing programmatic queries and submitting them via the
API, similar to our application in CROssBAR-WS to con-
struct the knowledge graphs. Currently, CROssBAR knowl-
edge graphs do not include PubChem data due to both
elevated computational demand (the sizes of PubChem
collections are large) and high redundancy (a large por-
tion of bioactivity data points in PubChem and ChEMBL
databases are shared). However, it is possible to query the
CROssBAR-DB using the provided API service, to obtain
data entries from PubChem database collections.
Deep-learning-based prediction of bioactivities
Bioactivity dataset construction. One critical topic in
developing drug/compound-target protein interaction
(DTI) prediction models is the source dataset to be used in
system training procedures. It is especially critical to con-
struct large-scale DTI datasets to train deep-learning mod-
els. To address this issue, we prepared a DTI dataset from
the ChEMBL database that is suitable for training machine
learning systems, with standardized filtering operations on
targets, compounds and bioactivities. The dataset is peri-
odically updated with each ChEMBL database release. We
employed this dataset for the training and validation of the
deep-learning based DTI prediction models we developed
in the framework of the CROssBAR project, and also as the
source dataset for drug/compound-target interaction space
visualization (these methods are described below). It can
also be used for developing new DTI prediction models.
The current version of the bioactivity dataset (ChEMBL
v27) is available for public use in: https://github.com/
cansyl/CROssBAR/blob/master/CROssBAR DB API/
ChEMBL27 preprocessed activities sp b pchembl.zip.
Details regarding the dataset can be found in our previous
article (23).
Deep learning base predictor 1 – DEEPScreen. DEEP-
Screen was the first tool that we utilized to produce DTI pre-
dictions to be integrated into CROssBAR. DEEPScreen is
a high-performance drug–target interaction predictor that
uses deep convolutional neural networks and 2D structural
compound representations (i.e. simple images) to predict
their activity against intended target proteins. DEEPScreen
system is composed of 704 target protein specific predic-
tion models, each independently trained using experimen-
tal bioactivity measurements against many drug candidate
small molecules, and optimized according to the character-
istics of target proteins. The main novelty of DEEPScreen
is employing readily available 2D structural representations
of compounds at the input level instead of conventional
drug/compound descriptors (e.g. molecular fingerprints)
that display limited performance. DEEPScreen produces bi-
nary predictions, meaning that a compound is either pre-
dicted as active or inactive against a target protein. During
the development of this method, we also carried out cell-
based in vitro wet-lab experiments on computationally gen-
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Figure 2. CROssBAR database; (A) schema-like representation of the independent collections of CROssBAR Mongo NoSQL database, displaying cross-
collection relations; (B) CROssBAR database statistics displayed in a circular bar-graph layout, bar lengths are shown in logarithmic scale, each high-level
biomedical data component group is displayed with a different colour, grey curves show the matching components in different database collections (i.e. bars
connected with grey curves signify the same types of biomedical data -keys-, these mappings are utilized for relating independent database collections to
each other), green curves signify the biomedical relationships (e.g. drug–target protein interactions) between different CROssBAR components, statistics
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ing the accuracy of the prediction models, and gaining bio-
logical insight in the framework of health and disease, espe-
cially to contribute to the understanding of processes active
in liver cancer. DEEPScreen can be used for the fast screen-
ing of the chemogenomic space, to provide completely new
DTIs that can later be investigated experimentally within
the framework of drug discovery and repurposing (23). The
source code, datasets and the results of DEEPScreen are
available at https://github.com/cansyl/deepscreen.
To enrich the DTI data in CROssBAR, DEEPScreen
was employed to scan a considerable portion of the
chemogenomic space and predicted >21 million new
DTIs between 1.3 million drug candidate compounds
in the ChEMBL database and 532 target proteins.
A filtered version of these predictions (∼8 million)
was incorporated in CROssBAR and displayed to
users as part of CROssBAR-KGs. These predictions
can directly be downloaded from: https://github.com/
cansyl/CROssBAR/blob/master/CROssBAR DB API/
CROssBAR DEEPScreen Largescale DTI predictions
filtered.tsv.zip.
Deep learning base predictor 2 – MDeePred. Our second
deep-learning based DTI prediction system ‘MDeePred’
adopts the proteochemometric approach, where both the
compound and target protein features are employed at
the input level to model their interaction, which enables
the prediction of binders to under-studied or previously
non-targeted proteins (24). In MDeePred, multiple types
of protein features such as sequence, structural, evolution-
ary and physicochemical properties are incorporated within
multi-channel 2-D vectors, which is then fed to state-of-
the-art pairwise input hybrid deep neural networks, to-
gether with molecular fingerprint-based vectors of com-
pounds. MDeePred predicts real-valued drug/compound-
target protein interactions, which can be interpreted as com-
parable response values such as IC50/Kd/Ki/potency (24).
The source code and datasets of MDeePred are available at
https://github.com/cansyl/MDeePred.
In the framework of this study, we trained two MDeePred
prediction models, with the aim of incorporating their
DTI predictions to the COVID-19 CROssBAR-KG. One
of these models was trained using ChEMBL experimen-
tal bioactivity data of orthologous ACE/ACE2 receptors
from different organisms (i.e. human, rat, mouse and rab-
bit) and used for predicting new inhibitor drugs for hu-
man ACE2 receptor. The second model was trained us-
ing ChEMBL bioactivity data points that belong to 3C-
like proteinase sub-unit of replicase polyprotein 1ab of
closely related coronavirus strains (i.e. SARS, MERS, Fe-
line and NL63 coronaviruses) and used for predicting new
inhibitor drugs for SARS-CoV-2 3C-like proteinase. For
both models, only ∼10 000 drug entries in the DrugBank
database (the ones with investigational and approved drug
status) were used as the query/test set, since the princi-
pal requirement for new potential COVID-19 treatments
is to be exempt from early drug development procedures
(e.g. pre-clinical analyses, phase I clinical trials, . . . ). Five
drugs with high predicted affinities (i.e. most of them with
predicted IC50 < 2 uM for 3C-like proteinase and IC50
< 100 nM for ACE2) were selected for human ACE2
(i.e. 7-hydroxystaurosporine, eribaxaban, becatecarin, tica-
grelor and amcinonide) and for SARS-CoV-2 3C-like pro-
teinase (i.e. diloxanide furoate, quinfamide, phenyl aminos-
alicylate, netarsudil and amlodipine) and included in the
COVID-19 CROssBAR-KG. Both the ChEMBL derived
training datasets of these models and the full prediction re-
sults are provided in the GitHub repository of the CROss-
BAR project (https://github.com/cansyl/CROssBAR). The
chemogenomic modelling approach used in MDeePred en-
abled us to provide predictions for these two targets, which
would otherwise be impossible due to the unavailability
of training data points, as both SARS-CoV-2 3C-like pro-
teinase and human ACE2 protein have insufficient number
of experimental bioactivity data points in source databases
for conventional ligand-based modeling.
Construction of knowledge graphs
In CROssBAR, the data is stored in a non-relational
database (MongoDB), as separate collections for easy
maintenance and fast querying. As a result, the database
itself is not a knowledge graph. Instead, biologically
relevant small-scale knowledge graphs are constructed
on-the-fly, triggered by users’ queries with a single
or multiple term(s) such as the names or identifiers
of genes/proteins, diseases/phenotypes, compounds/drugs
and/or pathways/biological processes of interest.
In CROssBAR knowledge graphs, biological entities are
represented as vertices/nodes. Distinct types of nodes are
defined for: (i) biomolecules (i.e. genes/proteins), (ii) bi-
ological mechanisms (i.e. pathways), pathologies: (iii) dis-
eases and (iv) phenotypes, small molecule ligands for treat-
ment: (v) drugs and (vi) drug candidate compounds. Rela-
tions between different types of biological entities are ex-
pressed by the edges of the graph. Edge types vary ac-
cording to defined relations. For a relation between; (i) two
genes/proteins, the edge is labelled as ‘interacts with’, (ii) a
gene/protein and a disease, the edge label is ‘is related to’,
(iii) a drug/compound and a gene/protein, the edge label
is ‘targets’, (iv) a gene/protein and a pathway, the edge la-
bel is ‘is involved in’, (v) a gene/protein and a phenotype
term, the edge label is ‘is associated with’, (vi) a drug and
a disease, the edge label is ‘indicates’, (vii) a disease and a
pathway, the edge label is ‘modulates’ and (viii) a disease
and a phenotype term, the edge label is ‘is associated with’
(Figure 1B).
A simplified form of the knowledge graph construction
workflow is displayed in Figure 3A. In this figure, parts
related to disease and gene/protein collection queries are
shown in full detail, and queries on the rest of the compo-
nents are simplified. The full-scale version of the knowledge
graph construction procedure is displayed in Supplemen-
tary Figure S1. Here, the finalized filtered dataset of each
biological component (i.e. genes/proteins, diseases, pheno-
types, drugs, compounds and pathways) is shown with a
shape surrounded by a black frame, and the graph is built
using entities/terms in these datasets, together with their in-
ter and intra-component relations.
Node filtering via overrepresentation analysis. Since the
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Figure 3. (A) Simplified workflow of the knowledge graph construction procedure, explained over an example disease term query. With the initiation of
graph construction by a disease query, the system: (1) finds the matching disease entry from the relevant collection, (2) gathers genes/proteins that are
associated with the query disease (i.e. core genes/proteins), (3) collects additional genes/proteins (i.e. first-neighbours) using PPIs of core genes/proteins,
(4) identifies biological processes (pathways), of which these genes/proteins (core + neighbouring) are members, (5) gathers phenotypic terms (HPO)
associated with the whole gene/protein set, (6) obtains known drugs and drug candidate compounds targeting these genes/proteins, together with our
deep-learning-based interaction predictions and (7) revisits the disease collection to make another query with all collected genes/proteins, to obtain the
disease entries that have similar implications as the query disease. The Full-scale workflow of the CROssBAR knowledge graph construction process is
provided in Supplementary Figure S1; (B) an example KG obtained from CROssBAR-WS, generated on-the-fly with the user’s query of ‘MAPK1’ gene
(with the node limit of 10 for each biomedical/biological component, and other default parameters), displayed under the layout selections of multi-layered
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all biological components/terms that are associated to the
query term(s) directly or indirectly, without further filter-
ing operations, searches would result in huge graphs com-
posed of tens of thousands of nodes and edges. In this case,
graphs would be unusable due to multiple reasons. First
of all, it would not be possible to visually perceive a bi-
ologically relevant result from the giant network. Second,
constructing and interactively displaying this graph would
have computational requirements so high that it would not
be feasible. To address this problem, we applied a multi-
staged overrepresentation-based enrichment analysis dur-
ing the construction of graphs. In this analysis, we calculate
an independent enrichment score for each biological entity
in the database (i.e. a disease, phenotype, drug, compound,
gene/protein or pathway), to be considered as its relevance
to the graph that is being constructed. The calculation of
enrichment score and its statistical significance is done us-
ing a modified version of the hypergeometric test for over-
representation (25), which also corresponds to one-tailed
Fisher’s exact test, and it is calculated based on the statis-
tics of relations/connections with gene/protein nodes. For
example, the enrichment score (ED,W) and its significance
(SD,W) in terms of P-value, for a disease term D, for graph























where ED,W is the enrichment score calculated for the dis-
ease term D for graph W; mD2 represent the square of
the number of genes/proteins in graph W that are asso-
ciated with disease D; nW represents the total number of
gene/protein nodes in graph W; MD is the total number of
genes/proteins (not necessarily in graph W) that is associ-
ated with disease D; and N represents the total number of re-
viewed human gene/protein entries (i.e. UniProtKB/Swiss-
Prot entries) in the CROssBAR database that is annotated
with any disease entry. SD,W represents the significance (P-
value) for the disease term D for graph W calculated in the
hypergeometric test.
Considering the enrichment analysis for diseases, while
constructing the graph, an enrichment score is calculated
for each disease entry in the CROssBAR database and these
scores are used to rank disease entries according to their bi-
ological relevance to graph W (i.e. in the order of decreasing
scores). A cut-off value k is employed to include the top k
relevant disease entries to graph W. The default value for
k is 10, which means that only top-10 relevant diseases will
be included. Apart from diseases, the same methodology is
used to filter out terms of neighboring genes/proteins, path-
ways, phenotypes, drugs and compounds. Significance val-
ues are not directly used in the filtering operation, since the
main objective here is not only including significantly over-
represented terms, but just reducing the number of nodes
in the graph by filtering out the ones that are least relevant.
Significance values are then calculated for the top 100 terms
from each biological component and displayed in query re-
ports for users who are interested. In the traditional way
of calculating an enrichment score, mD is without square.
The reason behind taking the square of mD here is mainly
to highlight the term with higher mD value (i.e. a higher de-
gree) in a case of multiple terms with very similar enrich-
ment scores.
Formalizing the graph construction around gene/protein en-
tries. During the construction of a knowledge graph, first,
the gene/protein entries that are directly connected to the
query term (i.e. core proteins) are fetched (e.g. member
genes/proteins of a queried signaling pathway). After that,
neighboring/interacting genes/proteins are added to the
graph by calculating enrichment scores for each interact-
ing protein, using the equation above, and filtering out
based on the selected cut-off value. This is followed by
the enrichment-based filtering and addition of terms from
other biological component types; however, this time, both
core and neighboring genes/proteins are taken into con-
sideration to calculate the enrichment scores. If the user
starts a heterogenous search that contains multiple terms
from different component types, both core and neighboring
genes/proteins are independently collected for each non-
protein query term, queried gene/protein entries are added
to this list (if there is any), and the term collection process
is continued using the union of these genes/proteins as the
source (Figure 3A). This approach enables the exploration
of direct and indirect relations between all query terms.
Gene/protein filtering based on source organism(s). We
set a taxonomic filter for the inclusion of gene/protein
entries in knowledge graphs, where the default selec-
tion is human (tax id: 9606), since the main focus of
CROssBAR is biomedicine. Even though there are en-
tries for proteins from hundreds of different organisms in
the UniProtKB/Swiss-Prot database, only a few of these
non-human protein entries possess annotations in terms
of pathway memberships, targeting drugs/compounds and
phenotype/disease implications. Thus, many of these pro-
tein entries are less useful in terms of constructing
biomedical knowledge graphs. Nevertheless, it is possi-
ble use the taxonomic filter in the web-service to in-
clude genes/proteins from a few additional organisms
namely, Rattus norvegicus (rat) [10116], Mus musculus
(mouse) [10090], Sus scrofa (pig) [9823], Bos taurus
(bovine) [9913], Oryctolagus cuniculus (rabbit) [9986], Sac-
charomyces cerevisiae (strain ATCC 204508/S288c) (Baker’s
yeast) [559292], Mycobacterium tuberculosis (strain ATCC
25618/H37Rv) (MYCTU) [83332], Escherichia coli (strain
K12) (ECOLI) [83333], severe acute respiratory syndrome
coronavirus (SARS-CoV) [694009] and severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2) [2697049].
Bioactive compound and bioactivity selection procedure.
Small molecule compounds are selected and incorporated
to KGs based on their reported bioactivities against target
proteins. In a KG, a compound is represented as a node and
a bioactivity is represented as an edge between a compound
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pound collection procedure with a set of target gene/protein
entries at hand (gathered in a previous step of the KG con-
struction process), and obtain the compounds that are re-
ported to be bio-actively interacting with these proteins,
as their targets. Despite having a simple logic, this proce-
dure is extremely complex due to practical reasons. Since
there are more than 15 million bioactivity measurements
in the ChEMBL database (v27), we rigorously filter these
data points with the aim of providing only the most rel-
evant bioactivity/compound information in CROssBAR-
KGs. Since CROssBAR is a gene/protein centric system,
we first filter out the data points where the target is not a
single protein. We also set an organism filter for the targets,
where the default selection is human. Additionally, we filter
out bioactivities if their standard (activity) type is not one
of these: IC50, EC50, AC50, XC50, Ki, Kd, potency; since
these standard types provide roughly comparable measures
of half-maximal response. Furthermore, we eliminated data
points without a pChEMBL value, which standardizes the
above-mentioned standard types under one number in the
negative logarithmic scale. Bioactivity data points with an
assigned pChEMBL value have usually received additional
curation, and thus, they are more reliable. Finally, with
the aim of only taking data points at the active binding
range (i.e. high affinities between the ligand and the tar-
get) we discard the data points with a pChEMBL value <5
(i.e. XC50 > 10 M). Despite these filtering operations, we
still usually end up with tens of thousands of compounds
before the compound enrichment analysis, which signifi-
cantly increases the KG construction run time. Exploiting
the fact that it is a better choice to include a compound
with higher binding affinity compared to a compound with
a lower binding affinity for the same target protein, we set
the pChEMBL value cut off value to 8, at the beginning
of the compound collection procedure. Then, we reduce the
cut off value and re-run the query if the total number of
gathered compound entries is less than 1000 in the first run.
We iteratively repeat this procedure until we obtain at least
1000 compound entries. Similarly, if the number of returned
compounds is >2500 in the first run, we further increase the
cut off iteratively until we obtain <2500 compound entries.
This number (i.e. 1000–2500) is still much higher than the
number of compounds we incorporate to a KG, which is
between 0 and 50; however, we aim to enter the enrichment
analysis with a high amount to be able to select the com-
pounds that are interacting with multiple proteins in the
network, not just one. Another reason is to be able to select
diverse compounds, in terms of their scaffolds/structures,
which is explained below (under the compound clustering
sub-section).
Compound clustering. There are more than one million
compound entries in the ChEMBL database, most of which
have bioactivity data points against target biomolecules.
Since it is not feasible to include each and every bioactive
compound node in a KG (otherwise the graph would be
extremely crowded), only the most overrepresented com-
pounds are tried to be incorporated. We observed that some
of the compounds with the same (or a very similar) enrich-
ment score(s) are also structurally very similar to each other.
These are mostly molecules with matching scaffolds, which
are screened against the same target and produced similar
results in the same bioassay. Since their enrichment scores
are similar as well, they are either selected or discarded to-
gether. To provide a better selection of compounds in the
graph, we incorporated a structural property-based filter-
ing in the enrichment analysis. The aim here is to select
overrepresented compounds that are as diverse from each
other as possible in terms of molecular structures, so that
users will be provided with a variety of ligands for the target
proteins in the graph. To achieve this, we calculated pair-
wise molecular similarities between all compounds in the
CROssBAR-DB using circular fingerprints (ECFP4) and
the Tanimoto coefficient. After that, we clustered the com-
pounds based on a predefined similarity cut-off value of 0.5,
meaning that each cluster is composed of compounds that
are at least 50% similar to each other. The cluster infor-
mation is pre-calculated and recorded on our server. Each
time a knowledge graph is being constructed, enrichment
score ranked compounds are checked one by one in terms
of their cluster membership and if there already is a com-
pound from the same cluster in the graph, the compound
in turn is discarded (i.e. not incorporated into the graph).
The same clustering-based selection approach is applied to
incorporate compounds that are computationally predicted
to interact with the proteins in the graph.
Following the finalization of the compound nodes, we
check whether some of these compounds correspond to
drugs that are already incorporated into the KG (since
ChEMBL also contains bioactivity measurements belong-
ing to approved or investigational drugs), using the identi-
fier mapping between ChEMBL and DrugBank databases.
When a positive case is detected, we merge these two nodes
and set the node type as a drug, since drugs are consid-
ered more reliable in terms of evidence on their molecu-
lar properties and interactions, compared to drug candi-
date compounds. If there are interactions reported in both
DrugBank (as DTIs) and ChEMBL (as bioactivity mea-
surements), we place all of the necessary edges from this
drug node to the corresponding target protein nodes in the
KG.
Evidence-based labelling of compound-target relationships.
Relations that signify biophysical interactions between
drugs/compounds and target proteins are obtained from
three different sources with varying degrees of confidence.
The most reliable relation in CROssBAR-DB is obtained
from the DrugBank database, where the reported drug–
target interaction (DTI) is verified by extensive analyses
as part of an official drug development process. The data
that came second in terms of reliability are from bioac-
tivity databases such as ChEMBL. In these resources, re-
ported bioactivities are obtained by experimental bioassays;
however, they are not as extensively verified as in drug dis-
covery and development procedures. The third in the list
of interaction sources is the deep-learning based in-house
computational predictions that we produced. These predic-
tions are not verified by any experimental means so they
should be considered with caution, even though we car-
ried out numerous computational validation experiments
for all predictions and provided in vitro experimental ver-
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relations comprise the least reliable part of the DTI infor-
mation provided in CROssBAR-KGs. With the aim of pro-
viding this evidence-based relation confidence information
to users, we used edge labels in KGs. In terms of visualiza-
tion, these labels are encoded on graphs as colors, such that
green color corresponds to DTIs obtained from approved
or investigational drugs, blue color corresponds to experi-
mental bioactivity measures obtained from ChEMBL, and
the red color corresponds to computationally predicted in-
teractions. During the generation of KGs, if a specific rela-
tion is obtained from multiple sources (e.g. when the same
relation is reported both in DrugBank and in ChEMBL) the
edge label of the more reliable relation is incorporated. To
accomplish this task, KG construction process comprises
an edge label update procedure.
Another process we applied at this step is the edge
addition. Some drugs possess bioactivity data points in
ChEMBL in addition to their approved targets in Drug-
Bank. To detect this, we first do a mapping between
ChEMBL compound entries and DrugBank drug entries,
to find the equivalent ChEMBL entry for each drug. Af-
ter that, we identify the reported ChEMBL bioactivities be-
tween that compound and all of the proteins presented in
the KG. We add blue colored edges to represent those rela-
tions which were not already incorporated into the KG via
DrugBank. The same procedure is applied for adding red
colored edges to the drugs and compounds that possess ad-
ditional computationally predicted target interactions.
CROssBAR Web-Service, user interface and layout
CROssBAR Web-Service (CROssBAR-WS) comprises
both the backend and the frontend processes to construct
KGs and to display them to users. CROssBAR-WS uti-
lizes an underlying complex API query set that gathers
data from the CROssBAR-DB. The underlying API query
collects relevant terms (entries) from 9 independent CROss-
BAR database collections together with their relations,
and it is given in the GitHub repository of the project
(https://github.com/cansyl/CROssBAR). CROssBAR-WS
also contains a sophisticated graphical user interface that
runs on our server. Technologies (all open access) used in
the construction of CROssBAR-WS are PHP, JavaScript
(cytoscape.js), jQuery, CSS (BootStrap), MySQL.
A user query initiates the term (node) gathering pro-
cedure first from the related database collection(s), us-
ing the corresponding CROssBAR API(s). Together with
the terms that match the search term, the data regarding
related/connected terms are obtained from the correspond-
ing collection(s). After that, the next CROssBAR-DB col-
lection is queried with the terms gathered at the previous
step. The order of the API queries follows the logic de-
fined for the construction of the KGs, as given in Figure 3A
(simplified version), and in Supplementary Figure S1 (full
version). Following the initiation of a query, the growing
knowledge graph is displayed on the web-browser in real
time (using Cytoscape Web), starting from the collection
and filtering of core and neighboring genes/proteins. The
process is continued with the collection, filtering and ad-
dition of phenotype/pathway/disease terms, drugs, bioac-
tive compounds and predicted interacting compounds to
the KG (as nodes), together with their relations with
gene/protein nodes (as edges). The construction process is
finished with the addition of respective edges between non-
gene/protein nodes.
An important topic in graph/network visualization is the
layout. In CROssBAR-WS, we incorporated the standard
layouts of Cytoscape Web, such as circle, cose, grid and
concentric. However, none of these layouts were sufficient
for communicating highly heterogeneous graphs with seven
different types of nodes and nine different types of edges.
To address this problem, we developed the CROssBAR
layout, in which biological terms (nodes) from a specific
biological/biomedical component (e.g. diseases, pathways,
. . . ) are placed on circular points within a fixed radius. There
are two versions of the CROssBAR layout, nested layers
(default) and isolated layers. In the isolated version, each
layer is circularized independently (Supplementary Figure
S3), whereas in the nested version, layers are intertwined
(Figures 3B and 4A). With the aim of preventing overlap-
ping nodes, the radius of each circle is selected as a differ-
ent value in the nested version. Both versions come with
4-layer and 7-layer (default) display options, which can be
selected by the user solely based on visual preference. Bi-
ologically similar components are merged under one layer
in the 4-layer display. Curved edge style (i.e. unbundled-
bezier) is applied in all layout types to reduce the amount
of edge crossing. The output of an example ‘MAPK’ gene
query is shown in CROssBAR (nested) and circular lay-
outs in Figure 3B. More information regarding the usage
of CROssBAR-WS and its user interface can be found at
https://crossbar.kansil.org/tutorial.php.
CROssBAR web-service queries run in linear time and
the actual duration of the process is correlated with
the total number of core genes/proteins obtained within
the query, together with the annotation volume of these
genes/proteins. Highly studied genes/proteins usually have
high number of associations, which in turn, extends the
actual query runtime in practice. According to our tests,
most of the queries with disease, gene/protein, drug and
compound terms (in terms of both single and combina-
tory term searches) take 1–3 min to complete (from job
submission to the display of the whole graph). However,
most pathway and some phenotypic term queries take
longer, especially when the number of directly associated
genes/proteins is over one hundred. With the aim of cre-
ating a better user experience, we applied a procedure in
which the collected nodes and their edges are instanta-
neously and interactively displayed on the screen, before the
end of the job. This way, users do not have to wait for the
whole job to be finished before starting to explore the KGs.
A detailed runtime analysis is provided under the Results
section.
The entire CROssBAR web-service including the web-
site and the underlying API queries can be found in
the GitHub repository of the project (https://github.com/
cansyl/CROssBAR).
Generation of COVID-19 knowledge graphs
Construction of the large-scale COVID-19 graph started
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Figure 4. Example cases of data exploration using the CROssBAR web-service; (A) the output knowledge graph of trifluoperazine and gastric cancer query;
(B) critical signalling pathways and their relation to trifluoperazine and gastric cancer over critical genes/proteins and (C) target interaction similarity
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‘COVID-19’ (id: MONDO:0100096). We also incorporated
the disease term for ‘Severe acute respiratory syndrome’
(id: EFO:0000694) (the original SARS) into the graph
since SARS is better annotated compared to COVID-19.
The full-scale COVID-19 KG construction is continued as
follows:
COVID-19 related genes/proteins and PPIs. We ob-
tained COVID-19 related genes/proteins and their interac-
tions from IntAct database’s Coronavirus dataset (down-
loaded on March 2021). Unlike a genetic disease, human
genes/proteins represent only a portion of infectious dis-
eases due to host-pathogen molecular interactions. There-
fore, we aimed to incorporate SARS-CoV and SARS-
CoV-2 genes/proteins besides the host genes/proteins into
the graph. Without any filtering, the KG contained 2951
gene/protein and metabolite nodes from various organisms
and 7706 edges. Due to high number of genes/proteins
in the KG, there was a risk of incorporating non-
specific/irrelevant terms from the other biological compo-
nents at later steps. To address this risk, we applied sev-
eral filtering operations on this dataset. First, we elimi-
nated all non-gene/protein nodes and we discarded the
genes/proteins if the corresponding organism is not human
or SARS-CoV/SARS-CoV-2. Second, we eliminated the
protein entries that are not reviewed (i.e. not a member of
UniProtKB/Swiss-Prot) except SARS-CoV-2 ORF10 (ac-
cession: A0A663DJA2), which currently is an unreviewed
protein entry in UniProtKB/TrEMBL (as of March 2021).
We also filtered out a portion of the host genes/proteins
using interaction-based data using confidence scores re-
ported in IntAct. We discarded the edges between host pro-
teins and SARS-CoV and/or SARS-CoV-2 proteins if the
confidence score was <0.35. We also discarded the edges
between host proteins in the KG (i.e. neighboring pro-
teins) if their interaction confidence score is <0.6. We re-
moved the disconnected components made up of host pro-
teins, which were formed due to the edge filtering opera-
tion. Orthology relations between SARS-CoV and SARS-
CoV-2 genes/proteins were annotated with ‘is ortholog
of’ edge type. The subunits of large protein complexes
such as the NSPs of replicase polyprotein 1ab of SARS-
CoV/SARS-CoV-2 were mapped to their corresponding
protein complex nodes and excluded from the graph. Af-
ter these operations, the finalized number of genes/proteins
is 778 (746 host genes/proteins, and 15 SARS-CoV and
17 SARS-CoV-2 genes/proteins) and the total number of
edges (i.e. PPIs including both virus-human and human-
human associations) is 1674. After this point, we started
collecting new nodes and edges from various biological
components based on the overrepresentation analysis and
curation.
COVID-19 related drugs and compounds.
Approved/investigational drug interactions of COVID-19
related genes/proteins were retrieved from DrugBank
database, v5.1.6 release. To incorporate only the most
relevant drug-target interactions, a drug overrepresentation
analysis was applied with respect to the associations with
target genes/proteins in the KG using the hypergeometric
distribution, as described in the section entitled ‘Construc-
tion of knowledge graphs’. The selected drugs were mapped
to their corresponding protein targets via the edge label of
green color, as this represents the highest level of confidence
in terms of receptor-ligand interactions. DrugBank also
has a COVID-19 specific drug list, which includes a curated
list of drugs currently under research for COVID-19
treatment. These drugs were included in the KG as well.
Drugs without any known targets (or the targets are known
but not presented in the KG), were included by connecting
directly to the COVID-19 disease node. We also incorpo-
rated drug repurposing-based curated and experimental
results from critical SARS-CoV-2 related publications such
as Gordon et al. (26), and we mapped these interactions
to our KG with suitable edge labels based on the data
source. Finally, we added drug-disease relationships based
on reported drug indications obtained from the KEGG
resource. The KG contains well-studied drugs for COVID-
19 treatment such as Remdesivir (DB14761), Favipiravir
(DB12466) and Dexamethasone (DB01234) etc., as well
as rather under-studied or non-studied ones (in the con-
text of COVID-19) such as Isosorbide (DB09401) and
Rocaglamide (DB15495).
For the retrieval of compound-target interactions based
on experimentally measured bioactivities, ChEMBL
database (v27) database was utilized. We retrieved the
ChEMBL bioactivity data points in binding assays, where
the targets are human, SARS-CoV and SARS-CoV-2
proteins, where the pChEMBL value is greater than or
equal to 5. Enrichment analysis was applied to select the
most relevant ones. Here, only drugs/compounds with
enrichment scores greater than 1 and P-value less than
0.05 were considered. Compounds were clustered based
on Tanimoto coefficient based molecular similarities with
a threshold of 0.5, and top 5 overrepresented compound
nodes, that are in different clusters, were selected for each
target protein (if exist) and incorporated into the KG. We
also incorporated selected compound––host target protein
and compound––SARS-CoV-2 organism interactions from
ChEMBL’s SARS-CoV-2 curated dataset, including both
binding and functional assays. Finally, the edge labels are
set accordingly (i.e. blue colored edges).
For the computationally predicted drug and
compound––target protein interactions, our in-house deep-
learning-based tools DEEPScreen (23) and MDeePred
(24) were used. DEEPScreen large-scale prediction run
results were scanned and 326 bioactive drug/compound-
target interaction predictions for 18 human proteins
were incorporated to the KG following the application
of overrepresentation analysis, similar to the one applied
for selecting experimental bioactivities from ChEMBL.
We trained two prediction models, one for human ACE2
receptor protein and one for SARS-CoV-2 3C-like pro-
teinase using ChEMBL bioactivity datasets as our training
dataset. Both models were used to scan full DrugBank
drugs dataset to predict new binders for ACE2 and 3C-like
proteinase for in silico drug repurposing. The details of this
process are given under the Methods sub-section entitled
‘Deep learning-based predictors and dataset construction’.
We only incorporated five selected inhibitors for each
protein in order to avoid the crowding of the KG, however
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tory of the project (https://github.com/cansyl/CROssBAR).
The selected bioactive drug predictions for ACE2 are Erib-
axaban (DB06920), 7-Hydroxystaurosporine (DB01933),
Becatecarin (DB06362), Ticagrelor (DB08816) and Amci-
nonide (DB00288); whereas the predictions for the 3C-like
protease are Quinfamide (DB12780), Diloxanide furoate
(DB14638), Phenyl aminosalicylate (DB06807), Netarsudil
(DB13931) and Amlodipine (DB00381). These predicted
interactions are labelled with red colored edges.
We also merged nodes with respect to drug-compound
entry correspondences in DrugBank and ChEMBL
databases. This way, some of the drug nodes also contain
experimental bioassay-based relations (i.e. blue colored
edges) and computationally predicted relations (i.e. red
colored edges). At the end of these procedures, the total
number of drugs (nodes) in the KG is 158 and the total
number of drug interactions (edges) is 346. The total
number of drug candidate small-molecule compounds in
the KG is 167 and the total number of compound inter-
actions (edges) is 664. Out of all drug/compound-target
interaction edges, 120 correspond to drug development
procedures, 382 to experimental bioassays and 508 to
deep-learning-based predictions.
Pathways of COVID-19 related host genes/proteins. Sig-
naling and metabolic pathway information was taken from
Reactome (via CROssBAR database) and KEGG pathways
data sources. The most relevant pathways were determined
by overrepresentation analysis and mapped to the related
genes/proteins in the KG. Some of the incorporated path-
ways are directly related to SARS-CoV-2 infection such as
‘Viral mRNA Translation’ (R-HSA-192823), ‘Maturation
of replicase proteins’ (R-HSA-9694301) and ‘ISG15 antivi-
ral mechanism’ (R-HSA-1169408), and the others are in-
nate pathways of the host (human) such as ‘Endocytosis’
(hsa04144), ‘Cell cycle’ (hsa04110) or ‘NF-kappa B signal-
ing pathway’ (hsa04064). We also incorporated pathway-
disease relations (in the sense of pathways that are modu-
lated due to presence of certain diseases) based on the rela-
tionships obtained from the KEGG database. The finalized
number of pathways in the KG is 100 (32 for KEGG and 68
for Reactome, among which there are corresponding terms)
and the total number of gene/protein-pathway associations
(edges) is 1333 (557 for KEGG and 776 for Reactome).
COVID-19 related phenotypic implications. The resource
for the phenotype terms is the Human Phenotype Ontology
(HPO) database. For each phenotype term that is associated
with at least one gene in the KG according to HPO data,
we calculated an enrichment score and P-value via overrep-
resentation analysis. From the score-ranked HPO term list
we selected phenotype terms that are not in a close parent-
child relationship with each other in the HPO direct acyclic
graph. HPO also has a curated list of SARS related phe-
notype terms. These terms were also added into the net-
work and mapped to ‘COVID-19’ and ‘Severe acute respi-
ratory syndrome’ disease nodes if their associated genes are
not presented in the KG. This way, COVID-19 related phe-
notypes including symptoms such as Fever (HP:0001945),
Myalgia (HP:0003326), Respiratory distress (HP:0002098),
Immunodeficiency (HP:0002721) and etc. are included in
the graph. The finalized number of phenotype terms in
the KG (nodes) is 43 and the number of HPO term -
gene/protein associations (edges) is 2427. There are also 56
HPO term - disease associations.
Other associated diseases of COVID-19 related host
genes/proteins. The aim behind this step is collecting
non-infectious (mostly genetic) diseases that utilize the
same (or similar) biological mechanisms/processes of
human, so that it may indicate potential risks for COVID-
19 patients, or potential COVID-19 related repurposing
options for drugs that are currently used to treat these
diseases. For this, disease terms that are associated with
genes/proteins in the COVID-19 KG were collected from
the CROssBAR database resources: EFO disease col-
lection (mainly including OMIM and Orphanet disease
entries) and KEGG diseases database. The most relevant
disease terms were selected based on the results of the
overrepresentation analysis. Finally, disease-HPO term
relations were also integrated into the KG using the disease
association information provided in the HPO resource.
At the end of this step, diseases such as Small cell lung
cancer (H00013), Amyotrophic lateral sclerosis - ALS
(H00058), Bruck syndrome (Orphanet:2771), Osteosar-
coma (EFO:0000637), and etc. have entered the KG. The
finalized number of disease terms in the KG is 41 (19
for KEGG and 22 for EFO) and the number of disease -
gene/protein associations (edges) is 120 (67 for KEGG and
53 for EFO).
The finalized large-scale COVID-19 KG includes 1289
nodes (i.e. genes/proteins, drugs/compounds, pathways,
diseases/phenotypes) and 6743 edges (i.e. various types of
relations).
For the construction of the simplified COVID-19 KG, the
starting point was the COVID-19 associated proteins in the
UniProt COVID-19 portal (https://covid-19.uniprot.org/),
instead of the IntAct Coronavirus dataset. The remain-
ing steps of building the graph were mainly similar except
that, additional nodes representing the organisms: human,
SARS-CoV and SARS-CoV-2 were placed in the graph and
connected to the corresponding proteins. The aim here was
to prevent the presence of singleton protein nodes due to
the reduced number of included genes/proteins and PPIs
in the simplified graph. It is also important to note that
the simplified version is not just a subset of the large-
scale KG. Since the starting point of gene/protein collec-
tion were different between two KGs, the resulting graphs
have slightly different contents as well. For example, the
drugs Siltuximab (DB09036) and Pirfenidone (DB04951)
are specific to the simplified KG. The simplified COVID-19
KG includes a total of 435 nodes and 1061 edges. The de-
tailed statistics for both KGs are provided in Supplementary
Table S5.
For the Cytoscape network files of both COVID-19
KGs, overrepresentation analysis results, and for more in-
formation about the CROssBAR COVID-19 KGs please
visit the CROssBAR project GitHub repository at: https:
//github.com/cansyl/CROssBAR. For directly visualizing
and exploring the COVID-19 KGs interactively, please
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In vitro experimental procedures for chloroquine treatment on
liver cells
Cell culture. Normal hepatocyte-like epithelial Huh7 cells
and mesenchymal-like Mahlavu liver cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (Gibco/Thermo
Fisher Scientific), 0.1mM non-essential amino acids
(Gibco/Thermo Fisher Scientific), and 100 units/ml
Penicillin/Streptomycin. Cells were maintained in 37◦C in
a humidified incubator under %5 CO2.
NCI-60 sulforhodamine B(SRB) cytotoxicity assay. Huh7
and Mahlavu liver cells were grown in 96-well plates (1000–
200 cells/well) in an incubator for 24 h. Both Mahlavu and
Huh7 cells were treated with Chloroquine Phosphate (CQ)
and water control in 40 M to 0.3 M concentrations for
72 h. After fixation with cold 10% (w/v) trichloroacetic acid
(MERCK) for an hour at +4◦C, plate wells were washed
three times with ddH2O. Each well was stained with 50 l
of 0.4%SRB dye(Sigma-Aldrich) and incubated at RT for
10 min. To remove unbound SRB dye, wells were washed
with 1% acetic acid for four times and left to air-dying.
The protein-bound SRB was solubilized in 100 l/well 10
mM Tris-base solution, and the absorbance was measured
with 96-well plate reader at 515 nm wavelength (ELx800,
BioTek).
Gene expression analysis of chloroquine with NanoString
multiplex gene expression panel. Huh7 and Mahlavu liver
cells were treated with CQ at cytotoxic doses of 3.6 M and
12 M, respectively, for 48 h. NanoString nCounter multi-
plex gene expression analysis, which includes 770 genes and
various canonical pathways such as PI3K, MAPK, STAT,
RAS, Cell cycle, DNA damage control, apoptosis, Hedge-
hog, Wnt, Transcriptional regulation, chromatin modifi-
cation, and TGF-, was applied on the RNA extracted
from cells using the RNeasy mini kit (Qiagen), followed
by the hybridization with code sets and scanning using the
nCounter Digital Analyzer as instructed by the manufac-
turer (NanoString Technologies). Results were analyzed us-
ing the Advanced Analysis Module on nSolver™ 3.0 soft-
ware for quality control, normalization, and differential ex-
pression. The expression levels of each gene were normal-
ized to those of control genes. After obtaining the differ-
entially expressed gene list with the native software, a fur-
ther filtering operation was applied based on the P-value
(i.e. <0.01), to identify the finalized list of genes with sta-
tistically significant expression changes. Differential expres-
sion of key pathways was revealed for both Huh7 and
Mahlavu cell lines using the fold change of the member
genes and their significance values. The resulting files are
provided in the GitHub repository of the project (https:
//github.com/cansyl/CROssBAR).
RESULTS
CROssBAR is composed of five sub-projects: (i) the con-
struction of the CROssBAR database and its API service
to house and serve the integrated biomedical data, (ii) train-
ing deep-learning based drug/compound-target protein in-
teraction (DTI) prediction models and their application
to identify previously unknown ligands for target proteins,
(iii) network based organization and analysis of large-scale
biomedical data using heterogeneous knowledge graph rep-
resentations, (iv) in vitro wet-lab experiments at different
levels of the project in order to validate/assess the relevance
of in silico generated knowledge and (v) the establishment
of an open access web-service, where user defined biomed-
ical term queries are processed via on-the-fly generation of
knowledge graphs with both tabular and network-based vi-
sualization and download options. CROssBAR system is
schematically represented in Figure 1A. The results and
outputs of these sub-projects are summarized below, also,
technical/methodological information is provided for each
one in the Methods section.
Constituents of the CROssBAR system
Biological data integration. CROssBAR database
(CROssBAR-DB) comprises selected features from
multiple data sources namely UniProt, IntAct, InterPro,
Reactome, Ensembl, DrugBank, ChEMBL, PubChem,
KEGG, OMIM, Orphanet, Gene Ontology, Experimental
Factor Ontology (EFO) and Human Phenotype Ontology
(HPO). Extract-Transform-Load (ETL) pipelines were
developed for heavy lifting of data from these resources by
persisting specific data attributes with the implementation
of logic rules. These pipelines fetch, cleanse, validate and
consolidate the data, and thus, implement a multi-omics
data integration approach to release a single resource
based on MongoDB collections. CROssBAR-DB, which
provides a broad spectrum of information such as biolog-
ical functions, domains, interactions, pathways, diseases,
phenotypes, drugs, compounds, and their associations with
biomolecules, is hosted and maintained by the EMBL-EBI.
The database schema-like representation and current data
statistics of the CROssBAR-DB are shown in Figure 2A
and B, respectively. CROssBAR-DB is periodically updated
on demand/request basis via an automated procedure,
which makes the underlying data up to date most of the
time. CROssBAR-DB can be queried via a public RESTful
API at: www.ebi.ac.uk/Tools/crossbar/swagger-ui.html,
which provides a multi-faceted view of the stored data
through 13 endpoints (Supplementary Figure S2). The
professional service providing approach applied in CROss-
BAR allows proper and constant maintenance of both the
database and its APIs.
Deep learning-based prediction of relationships. The iden-
tification of novel drug-like compounds and discovering
new usages of existing drugs are critical for drug discov-
ery and development. Traditionally, this is accomplished via
costly and time-consuming procedures and the rate of iden-
tifying novel drugs has decreased in recent years.
Out of all different biomedical entity relation types,
drug/compound-target protein interaction is one of those
with the highest rate of data incompleteness consider-
ing the current knowledge. There are >100 million dis-
tinct drug candidate compound records in public bioactive
chemical databases such as ChEMBL and PubChem, let
alone the theoretical number of all possible small molecules
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against hundreds of thousands of target biomolecules such
as single proteins and macromolecular complexes, the cur-
rent knowledge corresponds to <0.001% of the whole
compound-target space (27). The high rate of missing DTI
data negatively impacts the development of new computa-
tional methods in the field of drug discovery and develop-
ment as well.
To address this issue, we previously developed two novel
deep-learning-based predictive systems: DEEPScreen (23)
and MDeePred (24) as a part of the CROssBAR system,
to enrich the available bioactivity data by identifying un-
known interactions between drugs/drug-candidate com-
pounds and target proteins. DEEPScreen employs convo-
lutional neural networks to process 2D structural images of
drugs/compounds in 704 individually optimized high per-
formance target-based prediction models, suited for well-
studied targets (23). MDeePred utilizes both compound
and target protein features within a pairwise input hybrid
deep neural network architecture to produce real valued
bioactivity predictions, especially for targets with a few
training instances (24). We showed that, both of these meth-
ods perform better than the state-of-the-art DTI predic-
tors (in terms of prediction performance) on multiple hold-
out test datasets, furthermore, we validated them with ad-
ditional in silico and in vitro analyses (23,24). In the frame-
work of this study, we trained both systems using carefully
filtered and integrated data in CROssBAR-DB, and ran
our trained-models on large compound and human protein
spaces to obtain comprehensive bio-interaction predictions,
which are included in our knowledge graphs. We also de-
veloped an accompanying computational tool, iBioProVis,
which is an unsupervised-learning-based visualization sys-
tem for exploring large drug/compound-target interaction
datasets in reduced dimensions (28).
Knowledge graph representations. The term knowledge
graph (KG) defines a specialized data representation
structure, in which collections of entities (nodes) are
linked to each other (edges) in a semantic context
(29). In this study, we chose to represent heterogeneous
biomedical data using a KG-based structure. In CROss-
BAR knowledge graphs (CROssBAR-KG), biological
components/terms (i.e. drugs, compounds, genes/proteins,
bio-processes/pathways, phenotypes and diseases) are rep-
resented as nodes, and their known or predicted pairwise re-
lationships are annotated as edges (a protein and its coding
gene is treated as one merged term/entry/node). The logic
behind the construction of a knowledge graph is centered
around queried biological components/terms, as shown in
Figure 3A with a simplified workflow diagram and an exam-
ple disease term query. At each step of the KG construction
process, an overrepresentation-based enrichment analysis
has been performed to select the terms that are significantly
associated with the growing graph, and to discard the rest.
This analysis comprises a series of hypergeometric tests,
based on the recorded relations in the CROssBAR database.
Here, we applied a layered construction approach, always
taking the genes/proteins at the centre of the enrichment
analysis. Finally, additional relationships are incorporated
to the graph as edges between existing nodes (e.g. drug–
disease, disease–pathway and disease–HPO), to further en-
rich the provided relational information. During the con-
struction of graphs, terms (nodes) and their pairwise rela-
tionships (edges) are obtained from the CROssBAR-DB.
CROssBAR-KGs reveal the direct and indirect relation-
ships between all of the terms in the graph. These intensely-
processed heterogeneous biological networks are expected
to aid biomedical research, especially to infer mechanisms
of diseases in relation to biomolecules, systems and candi-
date drugs.
Open-access web-service. We developed the CROssBAR
web-service (CROssBAR-WS) to make CROssBAR-KGs
available to the public in an easily interpretable and inter-
active way (https://crossbar.kansil.org). KGs are presented
visually on web-browsers as flexible Cytoscape (30) net-
works. Users can create simple queries by typing names or
identifiers of biomedical terms, individually or in combi-
nation, to obtain a relevant graph of molecular relation-
ships. Combinatory term query is especially critical as it
provides the ability to investigate the indirect biological re-
lationships between the terms from both the same and dif-
ferent biomedical components. Since there are billions of
different ways to query CROssBAR, it was not feasible to
pre-calculate the resulting graphs; therefore, they are set
to be constructed on-the-fly, in real-time. Several options
are provided to users to customize the procedure both be-
fore and after the search, such as the UniProt databases
to be used (UniProtKB/Swiss-Prot or UniProtKB/Swiss-
Prot + UniProtKB/TrEMBL), taxon(s) to be selected,
inclusion/exclusion of experimental bioactivities and in sil-
ico DTI predictions, and the number of terms/nodes to in-
clude from each component type (which are selected based
on enrichment scores). It is also possible to display the
resulting graph using a variety of layout options, includ-
ing our in-house CROssBAR-layout with isolated (Supple-
mentary Figure S3) or nested (Figure 4A) layer versions
and 4- or 7-layer display choices. The interactive visual-
ization also lets users prepare a custom display by relocat-
ing the nodes/edges as desired. Saving options let users to
store the graph in different formats, including json, figure-
ready snapshots and protein-centric delimited data-tables.
Finally, at the end of each query, a report is provided with
the names, identifiers, enrichment scores and P-values of the
terms (including the ones that were not incorporated into
the graph due to low enrichment scores) are provided.
Biomedical data exploration via CROssBAR
It is possible to query CROssBAR with a combination of
terms which allows the user to investigate relationships be-
tween multiple entities of interest from the same or dif-
ferent biological/biomedical component(s). This type of
query may be composed of any number and combina-
tion of components (displayed in Figure 1B as nodes),
and the output knowledge graph will contain relation-
ships of different semantic interpretations (shown in Fig-
ure 1B as edges) directly or indirectly. Combinatory term
queries work with the same graph construction logic as
single term queries by collecting core genes/proteins and
expanding to other components from this core set. Con-
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sis involving a few genes/proteins, a signalling pathway, a
target disease together with its phenotypic implication(s),
one or more drug(s) and/or drug candidate compound(s)
that are being evaluated to intervene with the correspond-
ing pathology, the search is to be initiated by entering the
terms of interest to the dedicated fields in the CROssBAR-
WS interface (https://crossbar.kansil.org). Our automated
pipeline starts the KG construction process (as displayed
in Figure 3A within a simplified version and in Supple-
mentary Figure S1 in the full-scale) by first collecting the
corresponding database entries for all of the query terms,
which is followed by the identification and collection of
gene/protein entries that are directly associated with these
query terms (these association/relationship types shown in
Figure 1B), as core genes/proteins. In other words, this
core gene/protein set constitutes queried genes/proteins
plus genes/protein entries that are directly connected to the
queried pathway(s), disease(s), phenotype(s), drug(s) and
compound(s). Following that, neighbouring gene/protein
entries are collected using PPI data of core genes/proteins.
While finalizing neighbouring genes/proteins, an enrich-
ment analysis is applied to select only the most relevant
terms that are highly connected to the core genes/proteins
and infrequently connected to other gene/protein entries in
the database (number of the terms to be included in a KG
can be determined by the user). This is followed by the col-
lection of additional pathways, diseases, phenotypes, drugs
and compounds that are highly associated with the total
gene/protein set (core and neighbouring genes/proteins),
using the same enrichment-based filtering logic. Lastly,
non-gene/protein edges are identified and added to the
graph.
To provide an example on possible ways of using the
CROssBAR system, we explored the relation between a
drug (trifluoperazine) and a disease (gastric cancer), to
make a very quick and rough evaluation about the poten-
tial repurposing of this drug towards the disease of interest.
Trifluoperazine is an approved antipsychotic agent mainly
used in the treatment of schizophrenia (31). As far as we
are aware, trifluoperazine has no in vitro, in vivo or clini-
cal studies concerning the treatment of gastric cancer, al-
though there are studies on other types of cancer such as
colorectal (32), pancreatic (33) and lung (31), in the lit-
erature. Also, there is a study indicating the inverse asso-
ciation between antipsychotic use and the risk of gastric
cancer (34). Thus, this may be a convenient scenario for
investigating the relationship between two potentially re-
lated biomedical entities/terms, gastric cancer and trifluop-
erazine. To construct the corresponding knowledge graph,
we queried the CROssBAR-WS with these drug and disease
entries and selected the number of nodes to be incorporated
to the graph (from each biomedical component) as 20. The
resulting graph is shown in Figure 4A.
Trifluoperazine exerts its antipsychotic effect with the
blockage of dopamine D2 receptor. This relation is shown
in the graph, where trifluoperazine binds to the DRD2
gene/protein node and is associated with the dopaminer-
gic synapse pathway. In the KG, it is possible to observe
trifluoperazine’s other approved targets such as CALM1,
ADRA1A and TNNC1 proteins (approved drug-target in-
teraction edges are in green colour), and these proteins
are members of the calcium signalling pathway. Moreover,
DRD2 and CALM1 are associated with the rap1 signalling
pathway. Also, according to the KG, both calcium and rap1
signalling pathways have other gene/protein associations
such as ERBB2, KRAS and CDH1, which are further as-
sociated with the gastric cancer disease. In the light of these
relations, trifluoperazine can be explored via additional in
silico, in vitro / in vivo and clinical studies, in terms of its
potential to become a repurposed agent for the treatment of
gastric cancer, which may show its activity on gastric cancer
cells via calcium (35,36) and rap1 signalling pathways (37)
(Figure 4B).
Some of the proteins that are associated with the gas-
tric cancer (e.g. KRAS, ERBB2, TP53, etc.) are also re-
lated to other cancer disease nodes in the graph such as
the pancreatic cancer, ovarian cancer, endometrial cancer
and cholangiocarcinoma, which means that trifluoperazine
may also have a potential against these cancer types, wor-
thy of further exploration. Other antipsychotic or anxiolytic
agents such as risperidone, haloperidol, perphenazine, bus-
pirone, droperidol, and prochlorperazine are enriched in the
network as well, which bind to DRD2, CALM1 and/or
ADRA1A. These drugs may also become alternative repur-
posed drugs for gastric cancer treatment or other cancers
presented in the KG. In addition to the above-mentioned
approved drug-target interactions, the graph also includes
enriched drugs and drug like compounds having experimen-
tally measured bioactivities from ChEMBL (shown with
blue coloured edges) or DTIs that are computationally pre-
dicted by our in-house tool DEEPScreen (shown with red
coloured edges) against the targets DRD2, ADRA1A, EBP
and SIGMAR1; which can also be considered for the dis-
eases in the graph. Finally, there are several phenotypic im-
plication terms (from HPO) on the KG, such as the abnor-
mal urine carbohydrate level and the congenital hypertro-
phy of retinal pigment epithelium, which are associated with
gastric cancer disease node and/or gastric cancer related
genes. These phenotypic implications could also be helpful
considering clinical studies.
Apart from the exploration of potential drug repur-
posing applications, a drug search on CROssBAR can
also be utilized towards identifying new drug-like com-
pounds with similar target-based bioactivities. This kind
of exploration can be useful for medicinal chemists and
other researchers working on drug discovery. It is generally
accepted that compounds with highly similar molecular
structures also have similar bioactivities; however, there
is no generally accepted approach for identifying com-
pounds that can be alternatives to an approved drug, when
there is no structural similarity between the drug and
the candidate compounds. In this example, we queried
Sorafenib (https://www.drugbank.ca/drugs/DB00398),
a drug approved for the treatment of primary kidney
and primary liver cancers, in CROssBAR-WS to con-
struct its respective knowledge graph (Figure 4C). An
interesting observation on the resulting KG are the
compound nodes: CHEMBL272938 (https://www.ebi.
ac.uk/chembl/compound report card/CHEMBL272938/)
and CHEMBL3910171 (https://www.ebi.ac.uk/chembl/
compound report card/CHEMBL3910171/), which con-
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out 10 of the approved target proteins of Sorafenib are
also the targets of these compounds) indicated by the
bioassay-based interaction data (blue coloured edges on
the graph) for CHEMBL272938 and by computationally
predicted interactions (red coloured edges on the graph) for
CHEMBL3910171. It is also important to note that, the
other half of the approved targets of Sorafenib could also
be shared with these compounds; however, we currently do
not have further experimental information about it. High
overlap between the targets may indicate the potential of
these compounds to be alternatives for Sorafenib; how-
ever, additional computational and experimental analyses
are required to comment further. It is also important
to note that this result could not be obtained with a
conventional molecular similarity search, since Sorafenib,
CHEMBL272938 and CHEMBL3910171 have dissimilar
structures (neither a substructure search, nor a pairwise
molecular similarity search––with the minimum similarity
threshold of 40%––on the ChEMBL database could detect
any similarity between these three molecules).
COVID-19/SARS-CoV-2 molecular relationship KGs
As a use case of the system, we present Coronavirus dis-
ease 2019 (COVID-19) CROssBAR-KGs (https://crossbar.
kansil.org/covid main.php). Starting from the end of 2019,
the new coronavirus (SARS-CoV-2) pandemic has ravaged
the entire globe and caused immeasurable damage (38). As
of March 2021, the scientific endeavour to develop effective
drugs is still at peak, and systemic evaluation of the current
knowledge about SARS-CoV-2 infection is expected aid re-
searchers in this struggle. To demonstrate the capabilities
of CROssBAR, we have constructed two different versions
of the COVID-19 knowledge graph, (i) a large-scale ver-
sion including nearly the entirety of the related information
on different CROssBAR-integrated data sources, which is
ideal for further network and/or machine learning based
analysis or a detailed inspection (Figure 5A) and (ii) a sim-
plified version distilled to include only the most relevant
genes/proteins as provided in UniProt-COVID-19 portal
(https://covid-19.uniprot.org), which is ideal for fast inter-
pretation (Figure 5B). Technical details about the construc-
tion of COVID-19 graphs are given in the Methods section.
It is interesting to observe the indirect relations between
diseases/phenotypes in these KGs and COVID-19 over the
incorporated host proteins and enriched pathways, and be-
tween COVID-19 and our in silico predicted drugs, as they
may reveal further evidence to be utilized against COVID-
19 (Figure 5A and B). For this, we conducted a short
literature-based validation study and found that many of
these drugs have already been experimented at preclinical or
clinical stages for potential COVID-19 treatments (Supple-
mentary Table S6). Although these preclinical and clinical
studies are required to be completed before assessing the ef-
ficacy of these drugs, it is possible to state that CROssBAR
returned a few potential drugs (along with the ones that
have already been tested/used as part of different COVID-
19 treatment strategies), that might be interesting to explore
further with more directed in silico and/or in vitro / in vivo
approaches. Please refer to Supplementary Material section
1 for more information on this topic.
In vitro comparative study on liver cells
Although COVID-19 is a respiratory disease and lung
lesions have been considered the major damage caused
by SARS-CoV-2, liver injury has also been reported in
about one-third of hospitalized patients infected with
the virus and the majority of COVID-19 patient deaths
are associated with cytokine storm/release syndrome
resulting in multi organ damage (39). Hence, with the aim
of indicating the biological relevance of the information in
CROssBAR-KGs, we conducted in vitro experimentation
on drug treated liver cancer cell-lines and comparatively
analyzed the results on both COVID-19 KGs. Chloroquine
(CQ) phosphate has been used in treatment of COVID-19
with controversies (40) which was later revoked by FDA
(https://www.fda.gov/news-events/press-announcements/
coronavirus-covid-19-update-fda-revokes-emergency-
use-authorization-chloroquine-and). CQ is an anti-
inflammatory drug that has been used in autoimmune
diseases and can significantly alter the production of
pro-inflammatory and anti-inflammatory cytokines. We
investigated the effect CQ on normal hepatocytes like
Huh7 cells and poorly differentiated Mahlavu cells. Cells
were treated with CQ and the differentially expressed
gene (DEG) data were acquired from a large multiplex
panel of genes using the NanoString platform (Figure 6).
Our experimental data indicated significant alterations in
JAK/STAT, PI3K, MAPK and other pathways involving
cytokine production in liver cells (the full pathway list:
Supplementary Table S3). These pathways were also
presented in KGs along with additional cytokine related
pathways, such as interleukin signaling, along with dense
connections to other biological components in COVID-19
CROssBAR-KGs, which is biologically expected consid-
ering the mode of action of CQ in COVID-19. This way,
we showed a correlation between in vitro experimental
results (i.e. biological mechanism-based changes on CQ
treated cells) and the contents of the knowledge graph
that is constructed as a result of a relevant disease term
query, completely independent from the results of our in
vitro experiment. Since the information about the relations
of these pathways to COVID-19 and CQ is not directly
obtained from our source databases, this result indicates the
biological relevance of the data presented by CROssBAR.
In this sense, CROssBAR system can be utilized towards
the systematic analysis of pharmacological effects of drugs
as it brings relevant pieces of biological data together which
can be manually explored by the expert user to build new
hypotheses.
Analysis of knowledge graph diversity and stability
Highly studied biological/biomedical entities (e.g. TP53
gene, JAK-STAT signalling pathway, etc.) usually have high
a number of recorded relationships in databases. Conse-
quently, they often appear in biological networks or in the
resulting overrepresented term lists of gene set enrichment
analyses. In CROssBAR, we aim to construct knowledge
graphs with specialized content specific to the correspond-
ing query term(s), thus, we expect to observe diversity in our
KGs. Apart from that, we aim to produce stable outputs,







iddle East Technical U
niversity Library user on 17 O
ctober 2021
e96 Nucleic Acids Research, 2021, Vol. 49, No. 16 PAGE 18 OF 24
Figure 5. The use case of CROssBAR COVID-19 knowledge graphs (https://crossbar.kansil.org/covid main.php): (A) the large-scale KG (1289 nodes and
6743 edges) and (B) the simplified KG (435 nodes and 1061 edges). Both of these graphs reveal the most overrepresented biological processes during a
SARS-CoV-2 infection (i.e. cell cycle, viral mRNA translation, endocytosis, interleukin signalling, etc.), as well as, the potential treatment options with
COVID-19 related pre-clinical/clinical results (e.g. Remdesivir, Favipiravir, Dexamethasone, etc.) and our novel in silico predictions (for both virus and host
proteins) considering long-term drug discovery or short-term drug repositioning applications (e.g. tocilizumab, cyclosporine, becatecarin, tenecteplase,
simvastatin, etc.). It also displays rare and complex diseases and phenotypic implications with similar host protein associations (e.g. arthritis, diabetes,
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Figure 6. In vitro experimental results: volcano plots displaying differentially expressed genes in Chloroquine treated liver cells (Huh7 and Mahlavu). We
checked the interaction between the significant DEGs (Supplementary Table S2) and genes in the large-scale COVID-19 KG, and applied Fisher’s exact
test to analyse the significance of the presence of 36 DEGs on the KG (Supplementary Table S4) as opposed to the non-DEGs in the multiplex panel of
the gene expression analysis platform (NanoString). The results indicated that DEGs were significantly overrepresented (P-value = 1.5e–05).
related terms) should produce KGs with similar content, in
terms of incorporated nodes and edges. With the aim of in-
vestigating both diversity and stability of CROssBAR KGs
constructed as output of different biological/biomedical
term queries, we conducted two experiments. The first one
is a use case analysis, in which we independently queried
three different diseases (types of cancer), the first two of
which are similar to each other in terms of the affected bio-
logical mechanisms, and the third one is relatively dissimi-
lar to the first two in the same sense. For this, we selected
breast cancer, ovarian cancer, and osteosarcoma, respec-
tively. The reason behind selecting another type of cancer
as the third disease (instead of, for example, a rare disease,
which would be highly unrelated to the first 2 diseases) was
to create a rather realistic use case scenario that would allow
us to observe the issues related to graph diversity, if there are
any. Breast cancer and ovarian cancer are both associated
with mutations and/or overexpression/amplification in cer-
tain genes (e.g. BRCA1, BRCA2, PIK3C, ERBB2, etc.) and
aberrations in related pathways, which exhibits a risk of co-
occurrence in women (41–43). On the other hand, osteosar-
coma, the most common type of primary bone cancer, does
not have a known direct relationship with breast or ovarian
cancers. Besides, primary osteosarcomas of the breast and
ovary are reported as very rare malignancies (44,45). There-
fore, we expected to observe shared mechanisms/terms be-
tween KGs of breast and ovarian cancers, whereas the KG
of osteosarcoma was expected to be relatively more diverse.
We queried CROssBAR with these disease terms using
default parameter values (i.e. the number of nodes to be
included in KGs for each biological/biomedical compo-
nent is 10, organism: human, only include reviewed protein
entries from the UniProtKB/Swiss-Prot database) to con-
struct the KGs. The resulting graphs are composed of 162
nodes and 563 edges for breast cancer, 123 nodes and 397
edges for ovarian cancer, and 98 nodes and 208 edges for
osteosarcoma, and displayed in Supplementary Figure S3.
After that, we calculated pairwise and triple-wise intersec-
tions between the contents of these three KGs. Graphs that
are composed of intersecting nodes and edges are given to-
gether with Venn diagram-based statistics in Figure 7. We
observed that the content-based identity (i.e. presence of the
same nodes and edges) between KGs of breast and ovarian
cancers is around 30%, whereas the overall identity between
breast and osteosarcoma, and between ovarian and os-
teosarcoma are both ∼6%. It is also important to note that
both breast and ovarian cancer graphs contain the other dis-
ease as a similar disease node. It is observed from Figure 7A
and B that both BRCA1 and BRCA2 genes are presented in
breast-ovarian intersection, in addition to well-known can-
cer driver genes such as TP53, PIK3CA and ERBB2. Breast
cancer and ovarian cancer searches also contain other com-
mon associations such as pathways, phenotypes, drugs and
other diseases (e.g. ErbB signaling pathway, primary peri-
toneal carcinoma, paclitaxel, fallopian tube cancer, etc.).
Their differences are based on known and predicted bioac-
tive compounds, due to the fact that these are selected from
large pools of compounds that have direct relationship to
the genes/proteins in the corresponding graph. When we
omit ligands and only focus on the biological mechanism
related components, the graph identity between breast and
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Figure 7. CROssBAR knowledge graph diversity analysis use case, intersection graphs between: (A) breast cancer and ovarian cancer, (B) breast cancer and
osteosarcoma, (C) ovarian cancer and osteosarcoma, (D) breast cancer, ovarian cancer, and osteosarcoma (triple-wise) queries. Venn diagrams displaying
the statistics of shared: (E) nodes and (F) edges, between KGs of different query terms.
and osteosarcoma intersection only included 3 nodes and 3
edges that involve the TP53 gene (Figure 7D), which was ex-
pected since TP53 mutations are critical in almost all types
of cancer (46). The results of use case analysis indicated that
CROssBAR constructs diverse and stable graphs specific to
the user query term(s).
Since the first analysis was only a use case conducted
on three sample disease queries, we decided to further in-
vestigate the matter with a quantitative test on a larger
dataset. In our second experiment, we aimed to evalu-
ate whether highly studied, and thus highly connected
biological/biomedical entities tend to be presented in our
graphs with high frequencies. This would be undesirable as
it would mean certain terms usually end up in the graphs
no matter what is searched for (i.e. the problem of lim-
ited diversity). To test this, we selected 20 terms from each
biological/biomedical component (a total of 140 terms)
that are among the most connected, by checking the num-
ber of their associations (degree) to different genes/proteins
in our database. Names and identifiers of selected 140 terms
are given in Supplementary Table S7. After that, we checked
how many times these highly connected terms are presented
in CROssBAR KGs. First, to construct these graphs, we
queried randomly selected genes/proteins, Reactome and
KEGG pathways, EFO and KEGG diseases, HPO terms,
drugs and compounds one by one, and in combination with
each other, on the CROssBAR web-service, resulting in a
total of 1365 KGs. These query terms are listed in Sup-
plementary Table S8, and resulting KGs can be found in
our GitHub repository in json format. To evaluate whether
selected highly connected terms are overly represented in
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dently for each term with the null hypothesis stating that the
corresponding term is presented in KGs with an observed
frequency (i.e. for a term D, observed frequency is given by:
gD/G, where gD: number of KGs where term D is presented,
and G: total number of KGs in the analysis) same as its ex-
pected frequency based on its general connectivity (i.e. for a
term D, expected frequency is given by: t*MD/Msum, where
t: number of terms/nodes in each KG from the same bi-
ological component as term D, MD: the total number of
genes/proteins that are associated with term D, Msum: the
total number of associations between all genes/proteins and
all terms in the same biological component as term D). In
the case that the null hypothesis is true, we would conclude
that the system is not successful in terms of eliminating
promiscuous/hub terms, and they are frequently presented
in KGs probably because they are connected to many other
terms in the database. On the other hand, a statistically sig-
nificant deviation from the null hypothesis with an observed
frequency of presence in KGs lower than the expected fre-
quency would indicate that these hub terms are not pre-
sented in KGs as it would be expected based on their high
connectedness, instead, they are successfully eliminated by
our pipeline. We left compounds out of this analysis since
their expected frequency values are extremely low due to
their high number (e.g. 654 051 compounds have at least 1
target association). The results of this analysis are displayed
in Supplementary Figure S4 as bar graphs drawn for each of
the 140 terms, where observed and expected frequencies are
shown within overlapping bars with different colours (‘*’ in-
dicate that the corresponding observed frequency is signifi-
cantly lower compared to the expected frequency). These re-
sults are also displayed in Supplementary Table S7 together
with contingency table values used in statistical testing and
the resulting significance (P-values). It is observed from the
results of this analysis that 117 out of 140 highly connected
terms are significantly less represented in CROssBAR KGs
compared to their expected frequencies. Among these 117
terms, 22 highly connected ones (e.g. 14 HPO terms, 2 Re-
actome pathways and 6 drugs) were not presented in any
KGs at all.
Furthermore, with the aim of calculating the diversity
of graphs independent from any set of pre-selected terms,
we calculated pairwise node identity percentages between
all KG pair combinations (930 930 measurements between
pairs of 1365 KGs) and drew a histogram of these values
in log scale (Supplementary Figure S5). This histogram in-
dicates that the node identity distribution roughly follows
a power law distribution in the linear-scale, except for 106
graph pairs with a node identity value of 100%. We inves-
tigated these cases and found out that they either belong
to query terms from two different source databases that in-
dicate the exact same biological entity (e.g. disease entries
from EFO and KEGG databases: ‘Orphanet:98820: Famil-
ial focal epilepsy with variable foci’ and ‘H02214: Familial
focal epilepsy with variable foci’) or query terms with a close
semantic relationship in the respective ontology (e.g. phe-
notype terms: ‘HP:0012693: Abnormal thalamic size’ and
‘HP:0012695: Decreased thalamic volume’, or Reactome
pathways: ‘R-SSC-937039: IRAK1 recruits IKK complex’
and ‘R-SSC-975144: IRAK1 recruits IKK complex upon
TLR7/8 or 9 stimulation’), that have the same gene/protein
associations. As a result, they should not be taken into ac-
count. The mean node identity value of the distribution
is 0.9% (dashed vertical line in Supplementary Figure S5),
which is significantly lower compared to the identity value
observed between KGs of 2 cancer types with similar bi-
ological mechanisms (i.e. breast and ovarian cancers with
30% pairwise node identity), even lower than the identity
value observed between KGs of 2 dissimilar types of cancer
(i.e. breast/ovarian cancers and osteosarcoma with 8% pair-
wise node identity) in the use case experiment given above.
It is also important to note that, approximately 98.8% of
the graph pairs have less than 10% node identity values, in-
dicating the high diversity of CROssBAR KGs.
Finally, we calculated observed frequencies of all terms
that are presented in our 1365 randomly generated KGs
and plotted the results as biological component specific bar
graphs, in which different terms are presented on the hor-
izontal axis and their respective observed frequencies are
shown on the vertical axis (terms are ranked from the high-
est observed frequency to the lowest) in Supplementary Fig-
ure S6. On each panel, terms from a distinct biological
component are shown, together with their mean values as
dashed lines. As shown in Supplementary Figure S6, ob-
served frequency values of even the most frequent terms are
considerably low (between 0.012 and 0.055) for all compo-
nents except KEGG pathways. Moreover, these most fre-
quent terms only constitute a very small portion of the to-
tal number of terms in their respective components, which is
also indicated by low component-wise mean observed fre-
quency values (dashed lines). For example, the mean fre-
quency value considering core proteins is 0.0025, meaning
that, on average a gene/protein is presented in only 1 out of
400 different KGs. Core genes/proteins with the highest ob-
served frequencies are LNMA (P02545), MAPT (P10636)
and RAB9A (P51151) with frequency values of 0.057, 0.043
and 0.036, respectively. KEGG pathways are presented in
KGs with a mean observed frequency of 0.035 (highest
among all biological components), and the most frequent
pathways are ‘Metabolic pathways’ (hsa01100), ‘Neuroac-
tive ligand-receptor interaction’ (hsa04080), and ‘PI3K-Akt
signaling pathway’ (hsa04151) with 0.227, 0.123 and 0.100,
respectively. This was expected since the total number of
KEGG signalling pathways are 248 and 10 of them are in-
cluded in each KG. Also, the one with the highest frequency,
‘Metabolic pathways’, is an umbrella term containing sev-
eral pathways. A list of frequent terms from all components
are provided with their respective observed frequency val-
ues in Supplementary Table S9.
Graph construction runtime tests
Building a CROssBAR knowledge graph is a complex pro-
cedure that involved multiple rounds of API queries and
quantitative analyses of query results to select biological
terms to be represented as nodes, which is followed by the
finalization of edges in-between. With the aim of observ-
ing the practicality of this procedure, we conducted run-
time tests where we measured the time (in seconds) that
pass from submitting the initial user query, to the final-
ization of the output KG. For this, we utilized the same
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tion, which are composed of single term searches of 198
genes/proteins, 92 Reactome pathways, 100 KEGG path-
ways, 99 EFO diseases, 100 KEGG diseases, 199 HPO
terms, 199 drugs and 186 compounds, together with 192
combinatory queries composed of one random term from
each component (i.e. gene/protein, pathway, disease, phe-
notype, drug and compound). The actual query terms are
given in Supplementary Table S8. The resulting runtimes
are shown in Supplementary Figure S7 as histograms, where
queries of distinct components are given in different panels,
and median times are indicated by vertical dashed lines. As
observed from Supplementary Figure S7, runtimes are vari-
able both between the queries of the same component and
across different components. Among single term queries,
drugs and Reactome pathways constitute the fastest queries
with median runtimes of 30 and 29 s, respectively, and HPO
terms constitute the slowest with 62 s. Besides, combina-
tory term queries took ∼70 s on average. These results in-
dicate that, on average, it is practical to query CROssBAR
web-service and generate KGs on-the-fly. It is also impor-
tant to note that runtimes are approximately linearly corre-
lated with the number of collected core genes/proteins, and
thus, querying terms that are associated with high number
of genes/proteins (i.e. complex signalling pathways, generic
HPO terms, etc.) can take significantly longer compared to
mean times shown here. Runtimes also depend on the avail-
ability of servers.
DISCUSSION
In this study, we presented CROssBAR, a new system
that consumes large-scale biomedical data from various re-
sources and distils it to present a coherent piece of informa-
tion, relevant to a user-queried biomedical concept, com-
municated via heterogeneous knowledge graphs. To build
CROssBAR, we constructed a NoSQL database and stored
the data, developed deep-learning based models to enrich
the data at hand by predicting missing DTI links, built net-
works of integrated information containing genes/proteins,
diseases/phenotypes, biological processes/pathways and
drugs/compounds, and presented all these to the life-
sciences research community in an open access, user
friendly web-service. Our main objective in developing
CROssBAR was bringing the biological big-data together
and presenting it to the user in a way that is easy to interpret.
It is up to the user to evaluate the integrated and enriched
data, and to draw conclusions from it. We expect that our
well-maintained and continuously developed service will
be adopted by researchers from various domains of life-
sciences such as systems biology, cancer research and drug
discovery, to aid their investigations by exploring high-level,
indirect relations between specific entities/terms across dif-
ferent biological and biomedical concepts.
The incorporation of pathway-related information (both
signaling and metabolic pathways) in CROssBAR is done
within a membership-based approach, where pathways are
expressed on the graph as single nodes, and the nodes of
pathway member proteins are connected to them via edges.
This approach leaves out the detailed reaction-based mech-
anistic information provided in pathway databases such as
Reactome and KEGG pathways; however, the inclusion of
this information via applying a pathway resource styled net-
work approach would prevent the generation of large het-
erogeneous networks composed of tens of different path-
ways and other components. Nevertheless, it is possible to
explore these pathways in detail using the provided links,
which takes the user to the corresponding page on the path-
way database. Both Reactome and KEGG pathways pro-
vide the same type of biological information at the level
of large-scale biological processes; however, Reactome also
divides these processes into sub-pathways, whereas KEGG
only provides the pathway information at a generic level. In
CROssBAR, due to the way the overrepresentation anal-
ysis is done, specific sub-pathways are incorporated from
the Reactome database in most cases, whereas, the generic
pathway information is incorporated to KGs via KEGG. As
a result, pathway information is displayed at different levels
of specificity, and thus, not redundant in knowledge graphs.
We presented a use case of the system by constructing
two COVID-19 knowledge graphs. First, the large-scale ver-
sion, in which nearly the whole of the COVID-19 related
data recently accumulated in our source databases are in-
tegrated, organized and presented. Second, the simplified
version, where the aim was to provide user with a source
that is suitable for quick exploration, since the large-scale
KG is not easily explorable due to its huge size. Since most
of the COVID-19 related data are still being integrated into
biological databases, the data could not be automatically
pulled to the CROssBAR database at the time of writing
this manuscript. As a result, we had to make manual in-
terventions to obtain the data from CROssBAR data re-
sources. We applied the same knowledge graph construc-
tion methodology incorporated in CROssBAR; however,
we also conducted manual curation to a certain extent. We
saved the pre-constructed KGs, which are directly accessi-
ble and viewable through the links given on our web-service
(https://crossbar.kansil.org/covid main.php). It is also im-
portant to note that, due to the content of integrated data
resources, CROssBAR primarily contains rare and complex
disease data, and mostly leaves infectious diseases out. Nev-
ertheless, the constructed COVID-19 graphs provide rich
biomedical information.
At each step of developing the CROssBAR system, we
considered its alignment with FAIR data principles (47)
to contribute to the movement towards fully open access,
standard and easily (re)usable biomedical data. Since we
mainly integrate data from other open access biomedical
resources, we did not create new identifiers; however, we
extensively share the identifiers in the source databases to-
gether with links, with the aim of making our data findable.
Considering accessibility, CROssBAR system is reachable
through various ways including the full open access API
and web-service (interactively displaying the knowledge
graphs) and through the project repositories (e.g. https://
github.com/cansyl/CROssBAR) which includes the source
codes and datasets. CROssBAR data is highly interoperable
as it mainly integrates heterogeneous biomedical data that
is normally scattered throughout many independent data
resources, and presents it in a coherent and standardized
form. CROssBAR is released under the Creative Commons
Attribution 4.0 (CC BY 4.0) license which mostly prevents







iddle East Technical U
niversity Library user on 17 O
ctober 2021
PAGE 23 OF 24 Nucleic Acids Research, 2021, Vol. 49, No. 16 e96
it with the reusability item of FAIR. It is also important
to note that, since CROssBAR is mainly obtaining its data
from other open access biomedical data services, their com-
pliance with FAIR principles affects CROssBAR’s align-
ment as well, even though this effect is only indirect. For
this reason, we plan to encourage biomedical data providers
to consider prioritizing FAIR compliance while developing
their own resources.
As future work, we plan to integrate additional biomedi-
cal resources to CROssBAR such as (i) the cell-type/tissue
based transcriptomics, proteomics and other omics based
data (e.g. glycomics, lipidomics, etc.) and genomic vari-
ation data (e.g. missense mutations, copy number varia-
tions, etc.) in relation to both biomolecules and patients
(i.e. from TCGA) especially to be associated with dis-
eases, (ii) evolutionary information such as paralogy and
orthology relations across biomolecules of different species,
(iii) biomolecular function annotations (e.g. GO terms, EC
numbers), (iv) data sources and tools for infectious dis-
eases and their mechanisms and (v) literature-based in-
formation (e.g. articles) as evidences of incorporated rela-
tionships. Furthermore, we plan to enhance evidence-based
edge weights/labels in our knowledge graphs (currently we
have PPI confidence scores and DTI bioactivity values as
edge attributes), and also, to incorporate edge weights to
the enrichment analysis procedure, with the aim of assess-
ing the relevance of each biological term to the user’s query
with a higher specificity. We also plan to incorporate in sil-
ico relationship predictions between different layers of the
biomedical data, in addition to compound/drug-target pro-
tein interactions, such as gene/protein-disease/phenotype,
gene/protein-function and drug-disease associations, by
both constructing novel in-house prediction systems and by
incorporating approaches from the literature, including the
state-of-the-art graph learning-based link prediction meth-
ods. It is also important to state that, we continuously focus
on providing a well-maintained, fast, scalable and practical
service to the life-sciences research community with both
data updates and back-end/front-end improvements in our
resource.
DATA AVAILABILITY
CROssBAR web-service (including a tutorial on how to
use the service) is available at https://crossbar.kansil.org,
CROssBAR database is available through our API at https:
//www.ebi.ac.uk/Tools/crossbar/swagger-ui.html, all of the
datasets, results and the source code of this project
are available for download at https://github.com/cansyl/
CROssBAR, additional information is available in the
CROssBAR project web-site at https://cansyl.metu.edu.tr/
crossbar.
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